GLPwatch
Semaglutide
Approved · GLP-1 receptor agonist
Last updated 2026-05-28Semaglutide is a medication that mimics a natural hormone called GLP-1, which helps control blood sugar and appetite. It is sold under the brand names Ozempic, Wegovy, and Rybelsus, and is FDA-approved to treat type 2 diabetes, obesity, chronic kidney disease, and to reduce cardiovascular risk.
AI summary of the sources below.
| Mechanism | GLP-1 receptor agonist Mimics GLP-1, a gut hormone that raises insulin, lowers blood sugar, and reduces appetite. |
|---|---|
| Status | Approved |
| Branded products | ozempic, wegovy, rybelsus |
| Manufacturer(s) | novo-nordisk |
How Semaglutide connects
- Products OzempicRybelsusWegovy
- Treats Type 2 diabetesCardiovascular risk reductionChronic kidney diseaseObesity
- Maker Novo Nordisk
- Trials 440 trials
- Research 1,505 papers
Trials (440)
- A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in the United Kingdom, as Part of Local Clinical Practice
- Effect of Semaglutide on the Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus
- Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity
- A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects
- A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice
- Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM
- The Effect of Different Diets on Arterial Stiffness in Obese Patients on Semaglutide
- Semaglutide in Patients Undergoing Transcatether Aortic Valve Replacement
- A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice
- Research Study Comparing Different Tablets With the Study Medicine Semaglutide in Healthy Men
- A Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects
- The Effect of Semaglutide on the Intestinal Flora in Obesity
- The Semaglutide Study
- A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice (SURE NETHERLANDS)
- A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes
- Feasibility of Semaglutide in Advanced Lung Disease
- Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology
- A Research Study to Look at How Insulin Icodec and Semaglutide Work in the Body of People From China With Type 2 Diabetes When Given Alone or Together
- Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder
- Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes
- Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes
- Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.
- Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects
- Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice
- Gastric Ultrasound To Assess Gastric Contents In Patients On Semaglutide Therapy
Top research (1505)
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
- Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.
- Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.
- Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
- Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
- Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
- Semaglutide lowers body weight in rodents via distributed neural pathways.
- Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.
- Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
- Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.
- Once-Weekly Semaglutide in Adolescents with Obesity.
- Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.